Delcath Systems (DCTH) is presented as a high-risk, high-growth opportunity in liver cancer treatment, with its recent sell-off viewed as a buying opportunity given its exceptionally low valuation. TG Therapeutics (TGTX) is another high-conviction idea, considered poised to bounce after a recent 20% drop due to strong market share gains for its Multiple Sclerosis drug within a protected market. Management at TGTX has also raised guidance and expects a significantly stronger second half of the year, providing a potential near-term catalyst. In the beauty sector, consider avoiding e.l.f. Beauty (ELF) due to slowing growth and margin pressure from tariffs. Instead, Oddity Tech (ODD) is highlighted as a preferred alternative with higher margins and a direct-to-consumer business model.

Delcath Systems (DCTH)

• Business Focus: The company, referred to as "Delcalf" in the podcast, has developed a catheter system for treating a rare type of liver cancer called metastatic uveal melanoma.
• Market & Adoption:
  • The system allows for precision therapy to be injected directly into the liver.
  • Hospitals are reportedly "rushing to adopt the system" due to good patient outcomes.
  • The current target market is small, with about 800 patients per year, but the treatment is very expensive (recalled as $80,000 - $90,000), making the total addressable market significant.
• Growth & Financials:
  • The company is expanding faster than in the previous quarter, with revenue growing 22% quarter-over-quarter.
  • The speaker notes analyst growth estimates are around 120%, with some as high as 300%.
  • The company has paid off its debt and increased its cash reserves.
  • It achieved a 40% EBITDA margin in the most recent quarter.
  • Based on a 120% growth estimate, the Rule of 40 score would be 160 (120% growth + 40% margin), which is exceptionally high.
  • The speaker considers the stock "dirt cheap" with a valuation metric (EV/GP/RG) of 0.04.
• Future Potential & Risks:
  • Long-term story: Delcath is working on expanding its system to treat other types of liver cancer, which could increase its potential patient base to 40,000 per year. However, these new indications are not expected until 2027-2028 or later.
  • Risk: The company is currently a "one-trick pony," focused on a single type of cancer. The market's short-term focus led to a major sell-off after earnings, where the stock went from being up 21% to finishing the day nearly flat.

Takeaways

• Sentiment: The speaker is very bullish on DCTH for the long term, viewing the recent sell-off as a buying opportunity disconnected from the "outstanding" fundamentals.
• Investment Thesis: This is a high-growth, high-risk play on a disruptive medical device company. The investment case relies on the company's ability to capture its initial niche market and successfully expand into new indications over the next several years.
• Key Metric to Watch: Continued revenue growth and hospital adoption rates are critical. Any news on the progress of trials for other liver cancer treatments will be a major catalyst.

TG Therapeutics (TGTX)

• Business Focus: TGTX has a treatment for Multiple Sclerosis (MS) called Briumvi.
• Competitive Advantage:
  • Briumvi is a newer, quicker MS treatment with fewer side effects compared to competitors like Ocrevus.
  • The FDA has reportedly stated it is "done approving treatments for multiple sclerosis," creating a protected oligopoly for existing players like TGTX until 2042.
• Performance & Guidance:
  • The company is successfully taking market share.
  • It has raised its full-year guidance for the second consecutive time.
  • Management expects Q3 and Q4 to be significantly stronger than the first half of the year.
• Financials & Valuation:
  • The speaker views the stock as "cheap," with an EV/GP/RG of 0.21.
  • It has a Rule of 40 score of 72.
  • Projected forward growth is 53% with a gross margin of 87%.
• Future Potential: The company has "wild card" potential from other applications of its technology, including for Myasthenia Gravis.

Takeaways

• Sentiment: The speaker is very bullish, stating the stock is "poised to bounce" after a 20% drop that he feels was unjustified by the strong results.
• Investment Thesis: TGTX offers exposure to the biotech space with a strong competitive moat due to the FDA's stance on new MS drugs. The investment is based on continued market share gains and strong growth within a protected market.
• Key Metric to Watch: Look for continued market share gains for Briumvi and confirmation of stronger growth in the second half of the year as guided by the company.

e.l.f. Beauty (ELF)

• Business Focus: A popular cosmetics and beauty brand.
• Recent Performance & Concerns:
  • Revenue growth has slowed significantly to just 9% year-over-year, which the speaker finds "disappointing."
  • Sales are showing signs of "stagnation." The reason is unclear but could be due to competition or reduced marketing spend.
  • The company is being negatively impacted by tariffs, as 75% of its products are made in China, leading to a decline in profits.
  • The speaker believes the stock's recent 10% drop was "warranted" due to these concerns.
• Valuation: The speaker is no longer as enthusiastic about the stock at its current price of around $100, having preferred it when it was in the $50s.
• Positive Note: To combat the impact of tariffs, ELF increased prices by $1 on its products, effective August 1st, which should help profits recover.

Takeaways

• Sentiment: The speaker's sentiment has shifted from bullish to neutral/bearish at the current price. He is concerned about the significant slowdown in growth.
• Investment Thesis: While ELF is a strong brand, the slowing growth and margin pressure from tariffs present significant headwinds. The stock may be in a "show-me" phase where it needs to prove it can re-accelerate growth.
• Actionable Insight: The speaker now prefers competitor Oddity Tech (ODD) in the beauty space due to its higher margins and direct-to-consumer model. Investors looking for exposure to the beauty sector might consider comparing ELF to ODD.

Oddity Tech (ODD)

• Business Focus: A direct-to-consumer beauty and skincare company.
• Favorable Comparison to ELF:
  • The speaker mentions ODD as his new preferred investment in the beauty space over ELF.
  • It has a higher EBITDA margin (29%) and higher gross margin than ELF.
  • Its business model is fully direct-to-consumer.
• Potential Risk: The company's initial brand is still heavily focused on a single product category (foundation).

Takeaways

• Sentiment: Bullish. The speaker sees it as being in a "sweet spot" in the beauty industry.
• Actionable Insight: For investors interested in the beauty sector but concerned about the issues facing ELF, ODD is presented as a compelling alternative with a stronger financial profile and a more focused business model.